

**EFSD**

European Foundation for the Study of Diabetes

# **Report - 2011**

CONTENTS	PAGE
<b>Introduction</b>	4
<b><u>Grant Programmes 2011:</u></b>	
<b>EFSD</b> Clinical Research Grants in the Field of Diabetes	6
<b>EFSD</b> Research Programme in Diabetes and Cancer	7
<b>EFSD</b> New Horizons Collaborative Research Initiative	8
<b>EFSD/Amylin</b> Paul Langerhans Grants on Interaction between the Brain, Gut, Liver and Periphery and its Importance in Diabetes	9
<b>EFSD</b> European Diabetes Research Programme in Patient Education supported by an educational research grant from <b>AstraZeneca/BMS</b>	10
<b>EFSD/Chinese Diabetes Society/Lilly</b> Collaborative Diabetes Research Programme	11
<b>EFSD/JDRF/Novo Nordisk</b> European Programme in Type 1 Diabetes Research	12
<b>EFSD/JDRF</b> Young Investigator Awards in Innovative Therapy for Type 1 Diabetes supported by an unrestricted grant from <b>Roche</b>	13
<b>EFSD/Janssen</b> Programme for the Study of the Role of the Kidney in Diabetes	14
<b>EFSD/Lilly</b> European Diabetes Research Programme	15
<b>EFSD/Lilly</b> Mental Health and Diabetes Programme	16
<b>EFSD/Merck Sharp &amp; Dohme (MSD)</b> European Basic Research Programme on Beta Cell Function and Survival	17
<b>EFSD/Novo Nordisk</b> Partnership for Diabetes Research in Europe	18
<b>EFSD/Sanofi</b> European Research Programme in Micro- and Macrovascular Complications of Diabetes	19

## **Fellowships 2011:**

<b>EFSD Albert Renold</b> Travel Fellowships supported by <b>Merck Sharp &amp; Dohme (MSD)</b>	21
<b>EFSD/Chinese Diabetes Society/Lilly</b> Research Fellowships	22
<b>EFSD/Lilly</b> Research Fellowships	23
<b>EFSD/MSD</b> Fellowships for Research on the Endocrine Pancreas	24

## **New Programmes for 2012:**

<b>EFSD/Boehringer Ingelheim</b> European Diabetes Research Programmes	26
<b>EFSD/Janssen</b> Rising Star Fellowships	27
<b>EFSD/Japanese Diabetes Society</b> Reciprocal Travel Fellowships	28
<b>EFSD/JDRF/Novo Nordisk</b> Research Fellowships	29
<b>EFSD/Sanofi</b> Clinical Research Fellowships	30

*Note: the above relates solely to programmes which have been officially agreed at the time of writing this Report.*

---

<b>EFSD Review Committee Members</b>	31
<b>EFSD Executive Committee and Administration</b>	32

In 1999 the European Association for the Study of Diabetes (EASD) created its own Foundation - the European Foundation for the Study of Diabetes (EFSD) - in order to support more actively diabetes research in Europe and to serve even more effectively the goals of EASD, which are: to encourage and support research in the field of diabetes, to rapidly diffuse acquired knowledge, and to facilitate its application.

EFSD is a non-profit foundation, which seeks to support the highest quality research in Europe to find a cure for all types of diabetes and associated complications and to prevent their onset. EFSD aims to co-operate with other government and non-government agencies in order to increase funding in European diabetes research as a means of achieving its goals. Through its various activities and programmes, the Foundation also strives to enhance awareness in Europe of the severity and magnitude of this devastating disease. It is the ambition of the Executive Committee to develop EFSD as the main European funding agency for diabetes research.

The Foundation is closely related to EASD; it is governed exclusively by the Executive Committee of EASD, which itself is under the close supervision of the EASD Council and General Assembly. The Foundation operates on a strictly non-profit basis under the control of the relevant authorities in Germany.

### [EFSD and its partners bring over Euro 82 Million to European diabetes research](#)

In order to foster diabetes research at the highest level in Europe, EFSD has entered into innovative partnerships with other foundations and with industry. Through such partnerships, as well as its own stand-alone funding initiatives, to date EFSD has committed over **Euro 82 Million** to diabetes research in Europe.

Further information on EFSD Award Programmes is available on the website of the Foundation: [www.EuropeanDiabetesFoundation.org](http://www.EuropeanDiabetesFoundation.org). An RFA (request for applications) for each Programme is printed in *Diabetologia* (the official journal of EASD), and announced in the monthly e-mail sent to EASD members.

All applications are subject to rigorous peer review by a fully independent panel of leading experts in the field, and awards are based on scientific merit. Applications from non-profit organisations are welcome from Europe or any associated country as well as named non-European countries in the context of collaborative research programmes.

**EFSD**

European Foundation for the Study of Diabetes

**GRANT**

**PROGRAMMES**

**2011**

## Clinical Research Grants in the Field of Diabetes

### Plan

The EFSD Clinical Research Grants Programme was created to stimulate research into all aspects of diabetes, but with particular reference to epidemiology/genetics of prediabetes, diabetes and its micro- and macrovascular complications, pathophysiology and clinical aspects including vascular physiology and obesity. The proposed investigation must be carried out in humans; although in vitro and ex vivo studies are acceptable, the in vivo component must clearly be the more relevant part of the project.

### Funding Commitment and Instruments

Starting in 2007, this stand-alone EFSD Programme has committed a total of **Euro 6.2 million** towards clinical research in diabetes.

### Awards in 2011

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Constantinos Christodoulides: University of Oxford - UK

Luigi Gnudi: King's College London - UK

Neil Reeves: Manchester Metropolitan University - UK

Margaret Robertson: Surrey University - Guildford, UK

## Research Programme in Diabetes and Cancer

### Plan

The EFSD Research Programme in Diabetes and Cancer was established in order to stimulate and accelerate European research aimed at investigating why diabetes is associated with increased morbidity and mortality in certain forms of cancer. The role of diabetes therapy including molecular mechanisms is also of interest, and applications for projects carried out in collaboration between diabetes and cancer research institutions are especially welcome.

### Funding Commitment and Instruments

**Euro 3.75 million** has been made available from 2010 - 2013 in the framework of the Programme.

### Awards in 2011

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Pietro Formisano: Università di Napoli "Federico II" - Italy  
Derek LeRoith: Rambam Health Care Campus – Haifa, Israel  
Jaakko Tuomilehto: University of Helsinki - Finland  
Sarah Wild: Edinburgh University - UK

## New Horizons Collaborative Research Initiative

### Plan

There is a rich history of diabetes research throughout Europe and its associated states. Historically, however, funding for such research tends to be unevenly distributed. The Foundation now seeks to redress in part this imbalance and to foster inter-regional collaboration in diabetes research throughout Europe by making available grants through the EFSD New Horizons Collaborative Research Initiative

This Programme therefore aims to foster inter-regional collaboration in diabetes research throughout Europe on a competitive basis. It is open to investigators working in institutions in the following countries and proposing to collaborate with an investigator from a European country not on this list: Albania, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Georgia, Hungary, Latvia, Lithuania, FYRo Macedonia, Moldavia, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, and Ukraine.

### Funding Commitment and Instruments

Up to **Euro 2.4 million** was made available for the period 2009 - 2011 to fund basic and clinical research grants.

### Awards in 2011

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Gábor Firneisz: Semmelweis University - Budapest, Hungary *collaborating with Alexandra Kautzky-Willer: Medical University of Vienna - Austria*  
Igor Lacik: Slovak Academy of Sciences - Bratislava, Slovakia *collaborating with Terje Espevik: University of Science & Technology - Trondheim, Norway*  
Jan Lebl: Charles University - Prague, Czech Republic *collaborating with Torben Hansen: University of Copenhagen - Denmark*

# EFSD and Amylin

## Paul Langerhans Grants on Interaction Peripheral Tissues, the Gut and the Central Nervous System

### Background

Amylin Pharmaceuticals, Inc. was founded in 1987 on the discovery of a hormone, amylin, that is produced with insulin by beta cells. Built on a strong foundation of research, Amylin challenges conventional thinking to create innovative approaches to the discovery, development and commercialisation of novel therapies for metabolic diseases.

### Plan

EFSD and Amylin established a partnership in 2005 to provide grants for studies on the integrated physiology of the entero-insular axis and the brain in metabolic homeostasis, which evolved in 2011 to fund studies addressing the notion that the gastrointestinal tract plays an important role in the pathogenesis of diabetes. These grant awards honour the memory of Paul Langerhans, who discovered the islet cells of the pancreas.

### Funding Commitments and Instruments

Since its creation in 2005, the total funding commitment of the Partnership has reached **Euro 1.5 million**.

### Awards in 2011

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Rinke Stienstra: Radboud University Nijmegen - The Netherlands

Marie Björnholm: Karolinska Institute – Stockholm, Sweden

Angela Valverde: Spanish National Research Council (CSIC) – Madrid, Spain

# EFSD

## European Diabetes Research Programme in Patient Education

supported by an educational research grant from  
**AstraZeneca/BMS**

### **Background**

The AstraZeneca/Bristol-Myers Squibb diabetes collaboration is dedicated to global patient care, improving patient outcomes and creating a new vision for the treatment of type 2 diabetes.

### **Plan**

This Programme supports research into the clinical and medical evaluation of patient-related outcomes in relation to the type 2 diabetes chronic condition and the benefits of its treatment and management and the potential impact of educational and disease management programmes, focusing on holistic approaches to patients with type 2 diabetes, patient engagement and better understanding of the complex physiological and behavioural aspects of the disease.

### **Funding Commitment and Instruments**

A total of **Euro 1.2 million** for research funding will be distributed over three years from 2011 – 2013.

### **Awards in 2011**

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Kathleen Abu-Saad: Sheba Medical Centre - Ramat Gan, Israel  
Ingrid Mühlhauser: University of Hamburg - Germany

# EFSD and The Chinese Diabetes Society (CDS) and Lilly

## Programme for Collaborative Diabetes Research between China and Europe

### Background

Founded in 1991, the Chinese Diabetes Society conducts public education programmes, epidemiological surveys and research in China. The mission of CDS is to prevent and treat diabetes and provide information to help educate people living with diabetes, their families, health care professionals, and the public about this disease.

Lilly has for more than 85 years been a worldwide leader in diabetes care. Based in Indianapolis, USA Lilly introduced the world's first commercial insulin in 1923 and remains at the forefront of pharmaceutical and delivery-device innovation to manage diabetes.

### Plan

This partnership targets collaborative research endeavours between European and Chinese research centres and/or individual investigators in the area of diabetes and its complications.

### Funding Commitment and Instruments

Since its inception in 2008, a total funding commitment of **Euro 2.6 million** has been made to this Programme for research to be carried out in China in collaboration with a European research institution.

### Awards in 2011

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Ronald Ma: Hong Kong Institute of Diabetes & Obesity - China *collaborating with*  
*Mark Hanson: University of Southampton - UK*  
Youqing Wang: Beijing University of Chemical Technology - China *collaborating with*  
*Claudio Cobelli: University of Padova - Italy*  
Dijing Zhi: Fudan University - Shanghai, China *collaborating with*  
*Carani Sanjeevi: Karolinska Institute - Stockholm, Sweden*  
Lei Zhou: Huazhong Agricultural University - Wuhan City, China *collaborating with*  
*Jürgen Eckel: German Diabetes Center - Düsseldorf, Germany*

# EFSD and JDRF and Novo Nordisk

## European Programme in Type 1 Diabetes Research

### Background

The mission of JDRF is to find a cure for diabetes and its complications through the support of research. JDRF was founded in 1970 by parents of children with diabetes who were convinced that the disease could be cured. JDRF gives more money to diabetes research than any other non-profit, non-governmental health agency in the world.

Novo Nordisk A/S is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Novo Nordisk has companies and information offices in more than 60 countries.

### Plan

The EFSD/JDRF/Novo Nordisk Programme in Type 1 Diabetes Research aims to foster multi-disciplinary research targeted at finding a cure for type 1 diabetes and its complications.

### Funding Commitment and Instruments

The EFSD/JDRF/Novo Nordisk European Programme in Type 1 Diabetes Research was established in 2001 and has to date made a total combined commitment of **Euro 12.3 million**.

### Awards in 2011

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Mirko Pham: Heidelberg University Hospital - Germany  
Eliane Piaggio: Hospital Pitié-Salpêtrière - Paris, France  
Flemming Pociot: Glostrup Research Institute - Denmark  
Peter van Endert: Paris Decartes University - France

## Young Investigator Awards in Innovative Therapy for Type 1 Diabetes

supported by an unrestricted grant from **Roche**

### **Background**

The mission of JDRF is to find a cure for diabetes and its complications through the support of research. JDRF was founded in 1970 by parents of children with diabetes who were convinced that the disease could be cured. JDRF gives more money to diabetes research than any other non-profit, non-governmental health agency in the world.

Headquartered in Basel, Switzerland, **Roche** is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life.

### **Plan**

These Young Investigator Awards were established to promote increased European research in innovative therapy for type 1 diabetes, and to support young scientists within Europe during their transition towards independence.

### **Funding Commitment and Instruments**

A total commitment of **Euro 360,000** has been allocated to this Programme.

### **Awards in 2011**

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Eduard Ayuso: Autonomous University Barcelona - Spain  
Luc Baeyens: Free University Brussels - Belgium  
Paola Bonfanti: Free University Brussels - Belgium  
Geert Martens: Free University Brussels - Belgium

# EFSD and Janssen

## Programme for the Study of the Role of the Kidney in Diabetes

### Background

Janssen represents the pharmaceutical companies of Johnson and Johnson, one of the leading healthcare companies in the world. Janssen develops and markets innovative, high-quality pharmaceutical products and services aimed at improving quality of life for people with medical needs across the world, with metabolic diseases as a key area of scientific interest

### Plan

This Programme is intended to stimulate and accelerate European research aimed at understanding the role of the kidney in diabetes, with special emphasis on the role of the renal glucose threshold (RGT) as an underlying pathophysiologic mechanism in type 2 diabetes. Both basic and clinical research in this scientific area will be supported.

### Funding Commitment and Instruments

A total of **Euro 500,000** for research funding has been made available from 2001 – 2013 to support the award of grants.

### Awards in 2011

Based on the recommendations of the Review Committee, the Programme Board made an award to the following:

Paul Squires: University of Warwick - UK

## European Diabetes Research Programme

### Background

Lilly is a world leader in insulin production and also manufactures and markets a variety of other pharmaceutical products. The headquarters of Lilly is in Indianapolis, Indiana, USA.

### Plan

The EFSD/Lilly European Diabetes Research Programme is established within the frame of the EFSD/Lilly Fund. The goals of the Fund are: to promote increased European research in diabetes, support training and mobility programmes in diabetes research for young clinicians and scientists, and increase awareness of the burden of diabetes and its complications throughout Europe. Launched in 2003, the Fund has now reached a total commitment of **Euro 12.640 million** to fund its various activities, including research grant and fellowship programmes.

### Funding Commitment and Instruments

To date, the EFSD/Lilly Fund has committed **Euro 7.4 million** towards the EFSD/Lilly Diabetes Research Grant Programme.

### Awards in 2011

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Peter Arner: Karolinska Institute - Stockholm, Sweden  
Mireille Cormont: University of Nice - France  
Mirela Delibegovic: University of Aberdeen - UK  
Helene Duez: University of Lille - France  
Anthony Gavalas: Academy of Athens - Greece  
Eran Hornstein: Weizmann Institute of Science - Rehovot, Israel  
Joel Le Maoult: St Louis Hospital - Paris, France  
Carles Lerin: IDIBAPS - Barcelona, Spain  
Stefan Trapp: Imperial College London - UK

## Mental Health and Diabetes Programme

### Background

Lilly is a world leader in insulin production and also manufactures and markets a variety of other pharmaceutical products. The headquarters of Lilly is in Indianapolis, Indiana, USA.

### Plan

This Programme is aimed at clinical investigations into improved care of patients with diabetes and mental diseases including all forms of depression, schizophrenia and Alzheimer's. Special emphasis should be given to improving the co-operation between psychiatric and diabetes care.

### Funding Commitment and Instruments

In 2011, a further Euro 750,000 was allocated for a three-year programme from 2011 – 2013, bringing the total commitment to **Euro 1 million**.

### Awards in 2011

Based on the recommendations of the Review Committee, the Programme Board made an award to the following:

Geert Biessels: University Medical Center Utrecht - The Netherlands

# EFSD and Merck Sharp & Dohme (MSD)

## European Basic Research Programme on Incretins, Gut Physiology and Pancreatic Islets in Type 2 Diabetes

### Background

Merck & Co, Inc is a global research-driven pharmaceutical company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. Merck Sharp & Dohme, or MSD, is the name Merck uses for conducting its business in all other countries outside the United States and Canada.

### Plan

This Programme aims to stimulate and accelerate European research focusing on the following: incretin physiology, DPP-4 inhibition, gut physiology as it relates to metabolic control, and islet cell function and survival.

### Funding Commitment and Instruments

This partnership Grant Programme was established in 2005 and renewed in 2007 for a total commitment of **Euro 6.1 million**.

### Awards in 2011

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Gabriela da Silva Xavier: Imperial College London - UK  
Thierry Ferreira: Poitiers University - France  
Dominique Gauguier: Cordeliers Research Centre - Paris, France  
Guy Rutter: Imperial College London - UK  
Ram Weiss: The Hebrew University - Jerusalem, Israel

# EFSD and Novo Nordisk

## Partnership for Diabetes Research in Europe

### Background

Novo Nordisk A/S is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Headquartered in Denmark, Novo Nordisk has companies and information offices in more than 81 countries.

### Plan

This new Programme will accept applications from all fields of diabetes research, including both basic and clinical research.

### Funding Commitments and Instruments

This Programme continues the longstanding EFSD/Novo Nordisk Partnership, with a combined total commitment amounting to **Euro 8.9 million**.

### Awards in 2011

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Henning Beck-Nielsen: Odense University Hospital - Denmark  
Miriam Cnop: Free University of Brussels - Belgium  
Michael Elkin: Hadassah-Hebrew University - Jerusalem, Israel  
Luis Graca: University of Lisbon - Portugal  
Anders Rosengren: Lund University - Malmö, Sweden  
Hubert Vidal: South Lyon Medical Facility - France  
Suvi Virtanen: National Institute for Health and Welfare - Helsinki, Finland

## European Research Programme in Micro- and Macrovascular Complications of Diabetes

### Background

The sanofi-aventis Group is the world's third largest pharmaceutical company, ranking number one in Europe. Backed by a world-class R&D organisation, sanofi-aventis is developing leading positions in seven major therapeutic areas, and produces several medicines to treat diabetes including insulin. Their commitment to diabetes medicine has been longstanding since 1923 and the involvement of Hoechst, a legacy company of sanofi-aventis.

### Plan

The key objective of this research partnership is to understand better what best impacts cardiovascular risk reduction in patients with diabetes, aiming to evaluate the impact of any aspect of the following on CV risk reduction in diabetes: educational tools, programmes, strategies, risk assessment tools/screening and diagnostic procedures and clinical interventions.

### Funding Commitment and Instruments

Since its creation in 2006, the EFSD/Sanofi Partnership has made available a total of **Euro 3.6 million** to fund basic research projects.

### Awards in 2011

Based on the recommendations of the Review Committee, the Programme Board made awards to the following:

Tim Curtis: Queen's University of Belfast - UK  
Guiseppe Pugliese: La Sapienza University - Rome, Italy  
Casper Schalkwijk: University Hospital Maastricht - The Netherlands  
Sidney Shaw: University of Bern - Switzerland  
Marja-Riitta Taskinen: Helsinki University Central Hospital - Finland  
Thomas Wieland: University of Heidelberg - Germany

**FELLOWSHIP**

**PROGRAMMES**

**2011**

## Albert Renold Fellowships

Supported by an unrestricted educational grant  
from **Merck Sharp & Dohme (MSD)**

Albert Renold Fellowships, each of up to Euro 7,000, enable young scientists to travel to and stay at other institutions in order to learn new techniques in basic or clinical diabetes research. The duration of the stay should not exceed three months. Albert Renold Fellowships are available throughout the year, and a decision is usually made within three weeks of applying. Since its inception a total of **Euro 1 million** has been allocated to recipients of this Fellowship Programme.

In 2011 the following Fellowships were awarded:

Louisa Cheung: visiting Ranguel Institute - Toulouse, France  
Kyriakoula Marinou: visiting Oxford University - UK  
Zoltan Kender: visiting University of Heidelberg - Germany  
Michael Willenberg: visiting University of Maribor - Slovenia  
Konstantinos Michalakis: visiting University of London - UK  
Ellen Dirx: visiting University of Texas - Dallas, USA  
Julia Winkler: visiting Zurich Institute of Technology - Switzerland  
Melita Vidakovic: visiting Miguel Hernandez University - Elche, Spain  
Teatske Altenburg: visiting Baker IDI Heart & Diabetes Institute - Melbourne, Australia  
Elisa Corsiero: visiting Max-Planck Institute - Berlin, Germany  
Payal Nandkumar Shah: visiting Uppsala University - Sweden  
Merewyn Loder: visiting Kobe University - Japan  
Senthil Vasan: visiting University of Oxford - UK  
Silvie Timmers: visiting Federal Institute of Technology - Lausanne, Switzerland  
Alex Rafacho: visiting University of Geneva - Switzerland  
Nujen Colak Bozkurt: visiting University of Miami - USA  
Romyna La Rosa Vasquez: visiting San Carlos University Hospital - Madrid, Spain  
Daniele Lisboa Ribeiro: visiting Lund University - Sweden  
Berengere Valtat: visiting Lund University - Sweden  
Kathrin Schmeißer: visiting University College London - UK  
Tijana Mitic: visiting Monzino Cardiology Centre - Rome, Italy  
Christina Mallol: visiting Joslin Diabetes Center - Boston, USA  
Diana Rosa Milla Flores: visiting San Carlos University Hospital - Madrid, Spain  
Sandra Rebuffat: visiting Faculty of Pharmacology - Montpellier, France  
Margarita Jimenez Palomares: visiting University of Michigan - Ann Arbor, USA  
Tess Lu: visiting Research Center for Molecular Medicine - Vienna, Austria  
Peter Plomgaard: visiting University of Geneva - Switzerland  
Yvo Kusters: visiting University of Virginia – Charlottesville, USA  
Menang Joshua Ngwang: visiting Geneva University Hospital - Switzerland  
Jana Breitfeld: visiting University of Barcelona - Spain  
Alice Zoso: visiting University of Geneva - Switzerland  
Tina Ines Ullrich: visiting University of Alberta – Edmonton, Canada  
Valentina Di Caro: visiting University of Pittsburgh - USA

EFSD  
and  
The Chinese Diabetes Society (CDS)  
and  
Lilly

## Research Fellowships

The objective of the EFSD/CDS/Lilly Research Fellowships is to encourage collaborative research in the field of diabetes. Applications for fellowships may be accepted from young investigators from China for study in a recognised research institution in Europe or its associated countries. Details of the partner organisations may be found under “EFSD/CDS/Lilly Collaborative Research Programme”.

Two Fellowships of up to Euro 50,000 each are awarded annually. Application may be made by any paid-up member of EASD under the age of 38 years on the 1 January in the year of the Fellowship Award and with demonstrated ability in the field of diabetes research.

The Fellowship Programme was renewed for a three- year term in 2011, bringing the total funding commitment to date to **Euro 600,000**.

No awards were made through this Programme in 2011.

# EFSD and Lilly

## Research Fellowships

The objective of the EFSD/Lilly Research Fellowships is to encourage innovative research in the fields of metabolism and complications of diabetes, and to promote excellence in medical education. To date, **Euro 1.75 million** has been allocated to this Programme.

Each Fellowship Award is up to Euro 50,000. Application may be made by any paid-up member of EASD under the age of 38 years on the 1 January in the year of the Fellowship Award and with demonstrated ability in the field of diabetes research.

These Fellowships form part of the EFSD/Lilly European Diabetes Research Fund, further details of which may be found under "EFSD/Lilly Diabetes Research Programme".

In 2011 the following Fellowships were awarded:

Romain Barrés: University of Copenhagen - Denmark  
Federica Barutta: University of Turin - Italy  
Vladimer Darsalia: Karolinska Institute - Stockholm, Sweden  
Lorenzo Pasquali: IDIBAPS - Barcelona, Spain  
Matthew Simmonds: University of Oxford - UK  
Tom Van Belle: Ghent University - Belgium  
Nicolas Venteclef: Pierre and Marie Curie University - Paris, France

# EFSD and Merck Sharpe & Dohme

## **Fellowships for Research on the Endocrine Pancreas**

The objective of the EFSD/MSD Research Fellowships was to encourage innovative research focusing on the endocrine pancreas and to support talented young investigators engaged in diabetes research.

Postdoctoral Fellowships in the amount of Euro 50,000 were awarded to individuals already holding a PhD, MD or equivalent degree under the age of 38 years on 1 January 2011.

EFSD/MSD Fellows are expected to change their place and ideally country of work during the funding period in order to pursue their research project in a new academic environment. However, either the current home or proposed host institution must be based in Europe or an associated country.

These Fellowships form part of the EFSD/MSD initiative, further details of which may be found under the EFSD/Merck Sharp & Dohme Programme.

In 2011 the following Fellowships were awarded:

Shanna Tam: St Vincent's Institute, Fitzroy - Australia  
Jakob Wikstrom: Hebrew University, Jerusalem - Israel

**NEW  
PROGRAMMES**

**2012**

# EFSD and Boehringer Ingelheim

## European Diabetes Research Programmes

### Background

Boehringer Ingelheim is a global group of companies that seek to improve the health and well being of people and animals through being a part of an independent, innovative, research and development driven company.

### Plan

In order to encourage new projects aimed at advancing current knowledge in this domain, EFSD and Boehringer Ingelheim have established a new partnership called the EFSD/Boehringer Ingelheim European Diabetes Research Programmes. These Programmes consist of two elements, each with a different focus:

**Basic Research Programme:** *Regulation of Secretion and Function of Non-Insulin Peptides from the Endocrine Pancreas*

Applications dealing with research into the role, function and mechanism of non-beta cells are especially, but not exclusively, welcome.

**Clinical Research Programme:** *Mechanisms Relating Renal Dysfunction to Cardiovascular Disease in Type 2 Diabetes*

Projects investigating novel biomarkers or the translation of experimental hypotheses and clinical results are especially, but not exclusively, welcome.

### Funding Commitment and Instruments

A total of **Euro 2.5 million** for research funding will be distributed over three years in 2012 – 2014.

**The deadline date for this Programme is 1 April 2012.**

# EFSD and Janssen

## Rising Star Fellowships

The Rising Star Symposium aims to identify promising and innovative young researchers who are developing their research activities in Europe. Selected candidates will have the opportunity to present an overview of their past and ongoing research activities during a multidisciplinary research symposium at this year's EASD Annual Meeting. Four candidates will be selected, two in basic research and two in clinical research. The chosen candidates will be invited by EASD to present a lecture (25 minute lecture + 5 minute discussion) and will receive a commemorative diploma. Travel expenses, hotel and registration costs for the recipients will be covered.

Furthermore the award includes a research fellowship in the amount of Euro 30,000 payable to the applicant's institution. The objective of the research fellowship is to encourage innovative research in the field of diabetes. Applicants should have demonstrated their ability in the field of diabetes research.

Candidates for the Rising Star Symposium must be paid-up members of EASD and have a PhD, MD or equivalent degree. The candidates must be under the age of 38 on 1 January in the year of the award. Preference will be given to individuals who normally reside in Europe and who have consistently pursued a well defined and innovative research line, leading to several publications in high impact peer reviewed journals.

**The deadline date for this programme is 1 February 2012.**

# EFSD and Japan Diabetes Society

## Reciprocal Travel Research Fellowships

The objective of the EFSD/JDS Research Fellowships is to encourage collaborative research in the field of diabetes. Applications for Fellowships to carry out a scientific project will be accepted from applicants working in Japan to travel to Europe or its associated countries and also from those working in Europe or its associated countries to travel to Japan. The host institution must be a recognised academic research institution and applicants should have demonstrated their ability in the field of diabetes research.

Up to four Fellowships will be awarded, each in the sum of Euro 50,000. Awards will be paid into the account of the recipients' home institution. The scientific project will be three to twelve months in length with some extra time allowed to complete a language course. The budget may include items such as: salaries, travel, sustenance and consumables. The recipients must start the fellowship within 6 months of notification.

Applications may be made by any scientist or clinician who has been working in a postdoctoral position no longer than five years. Each applicant will need to provide a Letter of Support from both the home and the host institution.

**The deadline date for this programme is 15 March 2012.**

EFSD  
and  
JDRF  
and  
Novo Nordisk

## Research Fellowships

The objective of the EFSD/JDRF/NN Research Fellowships is to support young investigators engaged in research focused on type 1 diabetes and its complications.

Postdoctoral Fellowships, each in the amount of Euro 50,000, will be awarded to individuals already holding a PhD, MD or equivalent degree. Application may be made by any paid-up member of EASD under the age of 38 years on 1 January 2012.

Research Fellowships must be held at a non-profit institution. The present (home) and/or the host institution should be based in Europe or an associated country and any award will be transferred to a European institution account.

**The deadline date for this Programme is 1 July 2012.**

## Clinical Investigator Fellowships

The objective of the EFSD/Sanofi Clinical Investigator Fellowships is to encourage innovative clinical investigation and support talented young investigators engaged in diabetes research.

Postgraduate Fellowships, each in the amount of Euro 50,000, will be awarded to individuals already holding a basic medical qualification (MB, BS, MB ChB, MD, etc). Those holding higher degrees are also welcome to apply. All applicants must be paid-up members of EASD under the age of 38 years on 1 January 2012.

Research Fellowships must be held at a non-profit institution. The present (home) and/or the host institution should be based in Europe or an associated country and any award will be transferred to a European institution account.

**The deadline date for this Programme is 15 March 2012.**

## Review Committee Members

EFSD is most grateful to the following colleagues who served on the various review committees of the 2011 partnership programmes:

Bo Ahrén	David Klatzmann
Hadi Al Hasani	Filip Knop
Angelo Avogaro	Anna Krook
Francesco Beguinot	Agnés Lehuen
Christian Berne	Yannick Le Marchand-Brustel
Angelika Bierhaus	Johnny Ludvigsson
Nils Billestrup	Beat Lutz
Kåre Birkeland	Valeriya Lyssenko
Jonathan Bodansky	Sten Madsbad
Riccardo Bonadonna	Pierre Maechler
Ezio Bonifacio	Sally Marshall
Knut Borch-Johnsen	Nikolaus Marx
Miriam Cnop	Paolo Meda
Anne Cooke	Niels Møller
Leszek Czupryniak	Eduard Montanya
Hans De Vries	Ulrich Müller
Helena Edlund	Jacques Philippe
Decio L. Eizirik	Danny Pipeleers
Bo Feldt-Rasmussen	Arne Östman
Paola Fioretto	Andrew Renehan
Malin Flodström-Tullberg	Erik Renström
Edwin Gale	Guy Rutter
Mauro Giacca	Coen Stehouwer
Peter Grant	Jim Shaw
Fiona Gribble	Giatgen Spinas
Per-Henrik Groop	Norbert Stefan
Hans-Peter Hammes	Jean-François Tanti
Kristian Hanssen	Jeremy Tavare
Simon Heller	Bernard Thorens
Norbert Hermanns	John Wilding
Khalida Ismail	Yehiel Zick
Hannu Juvonen	Antonio Zorzano
Fredrik Karpe	

## EXECUTIVE COMMITTEE and ADMINISTRATION

### Executive Committee:

**President:** U Smith - Göteborg  
**Vice President:** F Bosch – Barcelona  
**Vice President:** A Boulton - Manchester  
**Honorary Secretary:** M Walker - Newcastle  
**Honorary Treasurer:** G Spinas - Zürich  
**Editor in Chief - *Diabetologia*:** J Zierath - Stockholm  
**Chairman PGEC:** C Tack - Nijmegen

**Chairman:** P A Halban - Geneva

**Scientific Board:** S Amiel – London  
F Beguinot – Naples  
F Bosch - Barcelona  
A Boulton - Manchester  
E Ferrannini - Pisa  
T Pieber – Graz  
G Soltész – Pecs  
M Stumvoll – Leipzig  
C Tack - Nijmegen

**Executive Director:** V Jörgens - Düsseldorf  
**Vice Director:** M Grüsser - Düsseldorf

The European Foundation for the Study of Diabetes (EFSD)  
Rheindorfer Weg 3  
40591 Düsseldorf, Germany

Tel: + 49 211 75 84 69-0 Fax: + 49 211 75 84 69-29

[www.EuropeanDiabetesFoundation.org](http://www.EuropeanDiabetesFoundation.org)

Email: [Foundation@easd.org](mailto:Foundation@easd.org)

### Bank Details

Europäische Stiftung für Diabetesforschung – EFSD  
Commerz Bank  
Königsallee 37  
40300 Düsseldorf, Germany

Account / Konto: 600 2146 00 Code / BLZ: 300 800 00

SWIFT / BIC: DRES DE FF 300 IBAN: DE31 3008 0000 0600 2146 00

EFSD is registered as a non-profit Foundation in Düsseldorf, Germany under registration number:15.2.1-St.767  
and at the Inland Revenue in Düsseldorf, Germany under tax number: 106/5744/1547